New Stocks to Watch


Brightpoint, Inc.(BrightPoint) is engaged in providing device lifecycle services to the wireless industry. The Company provides customized logistic services, including demand planning, procurement, inventory management, software loading, kitting and customized packaging, fulfillment, credit services, receivables management, call center services, activation services, Website hosting, e-fulfillment solutions, repair, refurbish and recycle services, reverse logistics, transportation management and other services within the global wireless industry. The Company’s has three geographic segments, the Americas, EMEA and Asia-Pacific. Its customers include mobile network operators, mobile virtual network operators (MVNOs), resellers, retailers and wireless equipment manufacturers. In March 2011, the Company acquired the business and assets of C20 Mobile Pte. Ltd. and C20 Corporation Pte. Ltd.


PURE Bioscience, Inc., formerly PURE Bioscience, is engaged in the development and commercialization of bioscience technologies. Its flagship bioscience technology is a aqueous antimicrobial called silver dihydrogen citrate (SDC). A molecular entity, SDC is an electrolytically generated source of stabilized ionic silver, which serves as the basis for a range of products in diverse markets. SDC liquid is colorless, odorless, tasteless, non-caustic and formulates well with other compounds. The Company is producing pre-formulated, ready-to-use products for both its own brands and for private label distribution, as well as varying strengths of SDC concentrate as an additive or raw material for inclusion in other companies’ products. It is also producing SDC as an active pharmaceutical ingredient, which is in clinical trials for multiple indications. In addition to SDC, it has obtained protection for ionic silver-based molecular entities utilizing 14 organic acids other than citric acid.


Cell Therapeutics, Inc. (CTI) develops, acquires and commercializes treatments for cancer. CTI is focused on the development, acquisition and commercialization of treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs. Its research, development, acquisition and in-licensing activities concentrate on identifying and developing less toxic ways to treat cancer. CTI is focused on Pixuvri (pixantrone dimaleate), or Pixuvri, OPAXIO (paclitaxel poliglumex), or OPAXIO, brostallicin and bisplatinates. It is developing a dinuclear-platinum complex. There are three platinates commercially available (cisplatin, carboplatin, and oxaliplatin), which are first-line agents in ovarian cancer, lung cancer, testicular cancer, and colorectal cancer, as well as a range of other diseases. CTI is developing the dinuclear-platinum complex CT-47463, which has a different mechanism of action than the platinum compounds.

Related Posts

Leave a Reply